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The solubility behavior of drugs remains one of the most challenging aspects in formulation development. 
Solid Dispersion (SD) has tremendous potential for improving drug solubility. Although praziquantel 
(PZQ) is the first drug of choice in the treatment of schistosomiasis, its poor solubility has restricted its 
delivery oral route. In spite of its poor solubility, PZQ is well absorbed in the gastrointestinal tract, but 
large doses are required to achieve adequate concentration at the target sites. The aim of this study was 
to improve the solubility and dissolution rate of PZQ and to evaluate its intestinal absorption. SDs were 
formulated with PEG-60 castor oil hydrogenated (CR-60) using a fusion and evaporation method. Pure 
PZQ and physical mixtures (PM) and PZQ-CR-60 (2:1; 1:1; 1:2 ratios) were compared as regards their 
solubility, dissolution and intestinal absorption. The experimental results demonstrated the improvement 
in the solubility, dissolution rate and intestinal absorption. In addition, the solubility behavior showed 
pH dependency and that the solubility of PZQ was slower in acidic medium than in neutral and basic 
mediums. The increase in PZQ solubility of the SD with the CR-60 could be attributed to several 
factors such as improved wettability, local solubilization, drug particle size reduction and crystalline or, 
interstitial solid solution reduction.
Uniterms: Solid dispersion. Praziquantel/dissolution rates. Praziquantel/solubility. Praziquantel/intestinal 
absorption.
A solubilidade de fármacos ainda é um dos principais desafios no desenvolvimento de formulações 
farmacêuticas. As dispersões sólidas (DS) apresentam grande potencial para melhorar a solubilidade de 
fármacos. O praziquantel é o fármaco de primeira escolha no tratamento da esquistossomose, contudo a 
baixa solubilidade em água restringe seu uso à administração pela via oral. Apesar da baixa solubilidade, 
o PZQ é bem absorvido através do trato gastrintestinal, mas doses orais elevadas são requeridas para 
garantir concentrações suficientes de fármaco para o tecido alvo. O objetivo deste estudo foi melhorar 
a solubilidade, a dissolução e avaliar a absorção do PZQ. As DS foram formuladas com óleo de castor 
hidrogenado - PEG 60 (CR-60), pelo uso dos métodos de fusão e evaporação do solvente. PZQ puro, 
mistura física (MF) e DS de CR-60-PZQ (1:2; 1:1; 2:1) foram comparados quanto à solubilidade, 
dissolução e absorção intestinal. Os resultados experimentais mostraram aumento na solubilidade, na 
taxa de dissolução e na absorção intestinal do PZQ nas DS. A solubilidade do PZQ foi maior em meio 
ácido, mostrando uma dependência do pH. O aumento na solubilidade do PZQ nas DS com CR-60 foi 
atribuída a fatores como aumento da molhabilidade, solubilização local, redução granulométrica e redução 
da cristalinidade ou, ainda, a ocorrência de uma solução sólida intersticial.
Unitermos: Dispersão sólida. Praziquantel/taxa de dissolução. Praziquantel/solubilidade. Praziquantel/
absorção intestinal.
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INTRODUCTION
With the advent of high throughput screening 
(HTS) for agents with potential therapeutic value, the 
number of candidate drugs which are poorly soluble in 
water has increased considerably. The formulation of 
these pharmaceuticals for delivery orally or systemically 
has become one of the greatest challenges faced by the 
pharmaceutical industry (Karavas et al., 2007). In recent 
years, studies on solid dispersion (SD) have shown this 
to be a promising route to improve the oral availability 
of those pharmaceuticals which have low solubility in 
water (Leuner, Dreesman, 2000). The term Solid Disper-
sion (SD) is used to describe a solid system in which the 
drug is dispersed in a biologically innocuous hydrophilic 
carrier. These systems are generally centered on the con-
version of a candidate pharmaceutical/carrier mix from 
liquid to solid state (Chiou, Riegelman, 1971; Corrigan, 
et al., 1979; Saito et al., 2002; Shim, Kim, 2003; Juppo 
et al., 2003; Liu et al., 2006; Ahuja et al., 2007). The 
aim of SD in pharmaceutical manufacture is to alter the 
solid state properties of the candidate pharmaceutical, 
thereby increasing dispersion rate, improving the solu-
bility coefficient as well as raising stability. Depending 
on the type of carrier used, this will change the release 
characteristics of the pharmaceutical (Sethia, Squillante, 
2003; Karavas et al., 2007). The technology of solid 
dispersion involves preparation of co-precipitates, co-
evaporates, nanoparticles, microcapsules, microspheres, 
and other products. One of the first publications on the 
concepts and advantages of solid dispersion formulas 
was published by Sekiguchi and Obi in the late 1970s 
(Sethia, Squillante, 2003). In their publication these 
authors presented a new method for reducing the size of 
poorly soluble particles in water by formation of eutectic 
mixtures. Law et al. (2003), applied the same principle 
to obtain eutectic microstructures with polyethylene 
glycol and fenofibrate. In a series of studies published 
by Goldberg et al. (1965(a), 1965(c), 1966(b), 1966(d)) 
the experimental details and theoretical advantages of 
a solution of solids, were presented. Chiou, Riegelman 
(1970) used polyethyleneglycol as a carrier and showed 
rapid and almost complete absorption, in vivo, of gris-
eofulvin. Saito et al. (2002), showed an increase in the 
solubility of griseofulvin using saccharides as carriers. 
Other carriers such as lactose, micro crystalline cellulose, 
chroscarmellose sodium, amide of sodium glycolate, 
polymethacrylates, have also been used to improve the 
absorption of pharmaceuticals that are poorly soluble in 
water (El-Arena et al. 1998; Cornier et al. 2000; Chowder 
et al., 2000; Babu et al. 2002; Law et al., 2003; Mitchell 
et al., 2003, Ohara et al., 2005; Karavas et al., 2007; Kim 
et al., 2008). Praziquantel (PZQ, 2-cyclohexylcarbonyl 
[1,2,3,6,7,11] hexahydro-4H-pyrazin [2,1a] isoquinolin-
4-one) is known worldwide as the drug of first choice 
for the treatment of the most common forms of schis-
tosomiasis and cysticercosis. These two diseases affect 
millions of people worldwide, especially those living in 
developing countries, and represent a very high social 
and economic cost to these countries (González-Esquivel 
et al., 2005). Although it is poorly soluble in water, 
PZQ is well absorbed in the intestine (Andrews, 1985; 
González-Esquivel et al., 2005). However, high oral 
doses are required to guarantee that sufficient concentra-
tions of the pharmaceutical reach the target larval tissues. 
At present, PZQ is available only for administration the 
oral route. However, alternative routes of administration 
and new drug forms could be considered if the problem 
of aqueous solubility was overcome. The objective of 
this study was to prepare solid dispersions by fusion and 
co-precipitation and evaluate, in vitro, the influence of 
these preparations of PZQ on solubility, dissolution rate, 
and intestinal absorption.
MATERIAL AND METHODS
Praziquantel (PZQ) was obtained with a purity of 
99.6%, from Induken Quimica Ltda (Brazil). The hy-
drogenate castor oil – PEG 60 (CR-60) was obtained, 
with pharmaceutical grade, from Henrifarma Química 
e Farmacêutica Ltda (Brasil). The supplier data had the 
following characteristics for the CR-60: melting point 
45oC, iodine value 0.26%, saponification number of 45-
50mg KOH/g, hydroxyl number of between 65-70 and 
pH 6.2 for 10% solution. TC-199 is the designation of the 
solution used to incubate the inverted intestinal sac and 
is composed of 145.0mM NaCl; 4.56mM KCl; 1.25mM 
CaCl2.2H2O; 5.0mM Na2HPO4 and 10.0mM of lactose.
Thermal analysis of Praziquantel 
Thermograms were obtained using DSC, DT/TGA 
analyzing instruments (Perkin-Elmer, Norwalk, CT). 
Temperature was calibrated using indium (156.6oC) as the 
standard. The operating conditions in an open-pan system 
were as follows: sample weight 5-10mg, 10 oC min-1 under 
N2 purging 50mL. min
-1. The temperature was increased 
from 25 to 600oC then allowed to decrease to 20oC.
Preparations of solid dispersions by fusion method 
PZQ and CR-60 were heated separately in a glycerin 
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bath up to 136-138oC under constant agitation until the 
mixture solidified by cooling. The SD was forced through 
a sieve with mesh openings of 0.35mm. 
Preparation of solid dispersions by co-precipitation 
method
PZQ and CR-60 were dissolved separately in etha-
nol, and mixed. The mixing time was 30 minutes, under 
mechanical agitation. The solvent was eliminated using a 
rotary evaporator (TE-210, Tecnal) under reduced pres-
sure. 
Preparation of physical mixtures 
The physical mixture (PM) of PZQ with CR-60 was 
produced using a mortar and pestle. The relative propor-
tions of CR-60: PZQ used in this SD and the PMs were 
1:2; 1:1 and 2:1. The products were kept shielded from 
light in a dessicator with a controlled humidity of (18% 
UR) until Constant weight, and were subsequently passed 
through another sieve in order to obtain a uniform surface 
area of the product. 
Evaluation of solubility 
The SD of PZQ and the PMs were dispersed in a 
distilled water solution, HCl 0.1N; Buffered phosphate pH 
7.4 or TC-199 and maintained horizontally with agitation 
for 12 hours at a temperature of 27±2oC. The concentration 
of PZQ was 1mg/mL in each dispersion medium. After 
this stage, the samples were first filtered with qualitative 
paper filters and subsequently passed through a filter with 
0.45mm pores. The tests were performed in triplicate and 
the quantity of PZQ dissolved was determined by spec-
trometry (l = 263nm).
Dissolution studies
This test was carried out using dispersion apparatus 
2 as described in USP-30, at 37oC and 75 rpm in 0.1N HCl 
with the addition of sodium laurel sulphate. The system 
was maintained in conditions of non-saturation of the dis-
persion medium. Samples of 5.0mL were taken at times 2, 
5, 10, 20, 50, 90 and 120 minutes, and immediately filtered 
through membranes with 0.45mm pores. The volume of the 
dissolution medium was maintained constant by the addi-
tion of 5.0mL of 0.1N HCl, kept at 37oC. The concentration 
of dissolved PZQ at each time point was determined by 
spectrometry (l = 263nm). 
Evaluation of intestinal absorption 
Intestinal absorption of PZQ was evaluated based on 
the SD of CR-60:PZQ in a 2:1 proportion and compared 
with the absorption of pure PZQ and PM. This experiment 
was conducted using male adult Wistar rats weighing 270 
± 20g. The animals were deprived of solid food for 8 hours 
before the start of the experiment. The rats were then anes-
thetized with Thiopental and the intestine dissected and 
immediately inverted with the aid of a cylindrical flexible 
rod, for exposure of the mucosal surface. An intestinal 
segment of about 8.0 cm in length from the pylorus was 
gently washed with TC-199 without glucose (10ºC). The 
intestinal segment thus formed was closed at one end with 
a suture, and filled with a solution of TC-199 without 
glucose. The other end was closed forming an inverted 
intestinal sac, which was immediately incubated in a 
previously oxygenated (95%O2:5%CO2) solution of TC-
199 (37ºC), with the addition of PZQ at a concentration 
of 1mg/mL. The incubation medium was kept under mild 
agitation while oxygenation was maintained by an oxy-
gen pump. The oxygen concentration of the medium was 
controlled with an oximeter (Oxygen Meter, Model OX). 
The quantity of PZQ absorbed was determined after 5, 10, 
20, 40, 80 and 120 min. of incubation. After these times, 
the intestinal segment was removed from the incubation 
medium and thoroughly washed in a physiologic solution. 
The contents of the intestinal sac were filtered in a 0.22mm 
pore membrane. The concentration of PZQ in the medium 
was determined by spectrometry (l=263nm). Permeability 
of the membrane was evaluated according to the transfer 
of glucose from the external to the internal compartment 
of the intestinal sac, as described by Barthe et al. (1999). 
Statistical analyses 
The results are expressed as mean ±standard devia-
tion. Parametric tests were used for the analysis of these 
results, taking into consideration the distribution of the 
values and the variability of the measures obtained. The 
level of significance was set at 5% (p<0.05) for rejection 
of the null hypothesis, where (*) indicates non significant 
intragroup values, and (#) indicates non-significant inter-
group values. 
RESULTS AND DISCUSSION 
The intestinal absorption of solid state pharmaceuti-
cals depends upon two processes which should occur in a 
consecutive fashion: (1) dispersion of the pharmaceutical 
in the gastrointestinal tract, and (2) transport of the dis-
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persed pharmaceutical through the blood. When the rate 
of dispersion of the pharmaceutical is significantly lower 
than the absorption rate, this becomes the limiting step in 
the absorption process. In order to choose techniques or 
procedures which can increase the solubility, a preliminary 
study of absorption needs to be carried out. The inverted 
intestinal sac model, when used in the phases of develo-
pment of a product, allows a comparative evaluation of 
the behavior of the pharmaceutical compound during the 
permeation phase (Balimane et al., 2000). 
Basic criteria and prerequisites for the selection of 
carriers were based on the possibility of increasing the rate 
of dispersion of the pharmaceutical using SD, pharmacolo-
gical inertness and pharmacotechnical functionality. It was 
also important for this study that the carrier had previously 
been approved for use by the Agência Nacional de Vigi-
lância Sanitária (ANVISA-National Health Surveillance 
Agency). CR-60 was also chosen for its tensoactive, sof-
tening and solubilizing properties. Finding physiologically 
compatible solvents capable of dissolving both hydrophilic 
and hydrophobic pharmaceuticals, and previously appro-
ved for this use by the respective governmental agencies, 
is challenging. Ethanol was chosen as a solvent for both 
the pharmaceutical and the carrier for this study. 
The term co-precipitate has been used by various 
researchers to denote SDs obtained by dispersion of both 
the pharmaceutical and the carrier. However, a better term 
for this process would be co-evaporation. Simonelli et al., 
1969 showed that these terms are conceptually different 
and used the term co-precipitation to describe dispersions 
obtained when a solution of sulphathiazole and PVP in 
NaOH was precipitated by the addition of HCl.
Thermal analysis of praziquantel
The results of thermal analyses of PZQ are shown in 
Figures 1 and 2. In the DSC (Figure 1) and DTA (Figure 
2), PZQ showed a sharp endothermic peak of 139oC, cor-
responding to the melting point of the racemic mixture and 
melting enthalpy of -96.4J/g. In the TG curve (Figure 2) 
PZQ has a single stage of thermal decomposition between 
200 and 300 ° C with a final residual mass of less than 
0.3%. These results are similar to those obtained by Liu, 
et al. (2004) and Torre et al. (1999).
Evaluation of solubility
The ratio of the quantity of CR-60 and PZQ were 
1:2; 1:1 and 2:1 (CR-60:PZQ), with the objective in this 
case being to evaluate the influence of the quantity of the 
carrier on the solubility. The dissolution profile of PZQ 
was verified only for the SD which showed optimal solubi-
lity. The effect of CR-60 on the solubility of PZQ in water, 
HCl 0.1N, buffered phosphate pH 7.4 and TC-199 are 
shown in Tables I-IV. Results are presented as mean±SD 
for n = 3. The solubility in TC-199 was verified with the 
aim of establishing a study model for in vitro intestinal 
absorption studies of PZQ. The solubility of pure PZQ in 
purified water, HCl 0.1N, buffered phosphate pH 7.4 and 
TC 199, was 52.63±0.169; 73.51±1.492; 45.43±0.405 and 
66.328±0.139 (× 10-1 mg/mL), respectively.
The solubility of PZQ in SDs with CR-60 was statis-
tically significant (p<0.05) in all of the dissolution media 
tested in this study, irrespective of whether PZQ was used 
in pure form or in a physical mixture. Solubility of PZQ 
was greater when the SDs were prepared using the Fusion 
Method and increased with higher concentration of CR-60. 
However, the SD obtained by the co-precipitation method 
was expected to yield superior results because the PZQ and 
CR-60 would be mixed in the molecular state.
FIGURE 2 - Representative TG/DTA of praziquantel.
FIGURE 1 - Representative DSC of praziquantel.
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TABLE I - Effect of CR-60 on the solubility of PZQ (× 10-1μg/mL) in water.
CR-60:PZQ DS (fusion) DS (co-precipitation) Physical Mixture
1:2 171.04±0.18 114.02±0.89 70.49± 0.75*
1:1 196.55±0.16 141.89±1.02 72.11±0.67*
2:1 269.31±1.41 209.96±0.65 79.49±0.14
TABLE II - Effect of CR-60 on the solubility of PZQ (× 10-1μg/mL) in HCl 01N.
CR-60:PZQ DS (Fusion) DS (co-precipitation) Physical Mixture
1:2 163.40±0.20 112.60±0.07 87.18±0.63
1:1 200.25±1.07 178.77±1.05 92.05±0.36
2:1 302.80±0.33 266.0±0.788 103.28±0.20
TABLE III - Effect of CR-60 on the solubility of PZQ (× 10-1μg/mL) in buffered phosphate pH 7.4.
CR-60:PZQ DS (Fusion) DS (co-precipitation) Physical Mixture
1:2 164.77±0.08 124.19±0.01 76.15±0.16
1:1 230.56±0.80 164.27±0.39 84.06±0.05
2:1 329.90±0.27 236.80±0.26 96.24±0.35
TABLE IV - Effect of CR-60 on the solubility of PZQ (× 10-1μg/mL) in TCC 199.
CR-60:PZQ DS (Fusion) DS (co-precipitation) Physical Mixture
1:2 131.00±0.16 105.77±0.14 58.15±0.78*
1:1 151.22±1.13 128.59±0.14 57.15±0.65*
2:1 259.91±1.68 188.17±0.25 71.78±0.80
Dissolution studies
The dissolution profile of PZQ in the SDs CR-60: 
PZQ (2:1) obtained by fusion and dissolution is shown in 
Figure 3 and compared to the dissolution profile of PZQ 
in physical mixtures and in the pure state. SDs and PMs 
presented a significantly greater dissolution rate than did 
pure PZQ. The result obtained from this dissolution study 
cannot be directly related with the evaluation of solubility, 
since it constitutes an exploratory study on the influence 
of the proportion of carrier (CR-60) on the pharmaceuti-
cal agent (PZQ). The dissolution rate of PZQ in an acid 
medium was higher than the solubility equilibrium rate 
(TABLES I - IV) where this is influenced by the processing 
conditions and by the presence of sodium lauril sulphate 
incorporated into the dissolution medium to maintain the 
non-saturated conditions of the medium (USP 30).
The improvement in the dissolution and solubility 
rates using the fusion methods could be ascribed to the 
saturation of the carrier by the pharmaceutical, associated 
FIGURE 3 - Dissolution profiles of PZQ with CR-60 (CR-60: 
PZQ - 2:1) in SDs. Co-precipitation (), fusion (), Physical 
mixture () and pure PZQ (). Each point represents the mean 
± standard deviation, n=6. 
with the increase in surface area and more rapid release of 
PZQ. The time to solidification of the liquid mixture can 
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be a critical factor in the saturation of the dispersed system 
(Chiou, Riegelman, 1971; Allen et al., 1977; Lin, Cham, 
1996). Dittgen et al. (1995) evaluated this parameter in 
the SDs of riboflavin, testosterone and progesterone and 
stated that the solubility of SD increased with reduced 
cooling time. In the present study, the dispersions were 
cooled naturally under constant agitation until solidifica-
tion. The rate of dissolution of PZQ also proved higher in 
the SD obtained by the Fusion Method. One of the factors 
responsible for this result is probably the saturation of the 
carrier by the pharmaceutical compound, which increased 
the liberation rate. This did not occur in the dissolution 
process with evaporation at low pressure, conditions which 
led to slow release of the solvent. Perhaps rapid removal 
of the solvent by lyophilization, “spray drying”, or under 
supercritical conditions would increase the solubility of 
PZQ in the SD obtained by dissolution. The dissolution 
rate would probably have been higher if the super satura-
tion of the pharmaceutical compound in the matrix were 
followed by a more rapid evaporation of the solvent. Ho-
wever, in this experimental model, the principal advantage 
of the dissolution method is the prevention of thermal 
degradation. Improvement in the dissolution rate of phar-
maceutical compounds in SD has been the subject of nu-
merous investigations, and increases of up to 400 fold have 
been reported (Sethia, Squilante. 2003). In spite of these 
studies, the mechanisms by which this occurs are poorly 
understood. In SDs, reductions in granulometry and/or 
interparticle cohesion forces leading to increase in surface 
area exposed to the solvent have been considered one of 
the principle reasons for the increase in the dissolution 
rate. Reduced particle size has classically been considered 
the result of the formation of the solid or eutectic solution 
(Craig, 2002). Notwithstanding, the intrinsic link between 
the solid state structure and the liberation of the pharma-
ceutical compound suggests that the particles are held in 
the dissolution medium as separate physical entities. This 
reduction in cohesion force, in addition to the wetting pro-
perties of CR-60, contributed toward increasing the rate of 
dissolution. While the mechanism by which the solubility 
and rate of dissolution of PZQ increases in SD is difficult 
to elucidate in this experimental model, it appears that the 
critical factor is the physical-chemical characteristic of 
CR-60. The tensoactive properties of this carrier appear 
to predict the mathematical model of Noyes-Whitney for a 
single-component system in which both the carrier and the 
pharmaceutical agent dissolve at rates proportional to their 
soluabilities and coefficients of diffusion. This doubt has 
raised several questions, such as: what factors determine 
whether the dissolution is controlled by the carrier or the 
pharmaceutical? What is occurring to the pharmaceutical 
during these preparations of SDs? And finally, what are the 
implications of understanding these mechanisms for the 
development of a pharmaceutical form and the use of SDs 
in industrial processes? The answers to these questions are 
being sought by our group through projects in progress, 
using infrared spectroscopy, X ray diffraction, differential 
exploratory calorimetric and process analysis.
Evaluation of intestinal absorption 
The inverted intestinal sac model is useful for studying 
physiological and molecular processes of absorption, provi-
ding physical and chemical information on the properties of 
the pharmaceuticals, and ascertaining the role of the absorp-
tion facilitators and inhibitors of intestinal metabolism. In this 
study, the intestinal inverted sac method was used to evaluate 
the influence of CR-60 on the intestinal absorption of PZQ. 
The glucose in the incubation medium (TC-199) was used to 
evaluate the permeability of the intestinal membrane and the 
viability of the enterocytes. The segment of small intestine 
of rats and its inversion was performed carefully using a fine 
silk covered Rod to avoid morphological damage. Due to the 
absence of blood and nerves these tissues have low viability. 
However, when kept at 37ºC in TC-199, these segments were 
morphologically intact and metabolically active for about 2 
hours. In this aspect, our results were similar to those descri-
bed by Barthe (1999) and Souza et al. (2007) who reported 
progressive increase in the glucose concentration in the inte-
rior of the intestinal sac for a 120-minute period. 
Absorption of PZQ was evaluated only for SDs 
with CR-60 and a ratio of 2:1 (CR-60:PZQ) because this 
showed optimal solubility, and given the knowledge that 
the bioavailability of PZQ is limited by its low solubility 
in water. The absorption of PZQ in SDs was compared 
with the absorption of pure PZQ and with PM (1:2). Figure 
4 shows the profile of intestinal absorption of PZQ over 
a 120-minute period. The results differed significantly 
(p<0.05) for SDs after 20 minutes of incubation compared 
to pure PZQ and PM. The improvement in the intestinal 
permeation is related to the increase in the dissolution rate 
of PZQ caused by CR-60 in SDs. 
In this study, the use of an inverted intestinal sac de-
monstrated that CR-60, used in the preparation of the SDs, 
increases the solubility, dissolution rate and consequently, 
the absorption of Praziquantel. The solubility profile as 
well as the velocity and extent of dissolution presented by 
the SDs, compared to pure PZQ or PM, can be explained 
by modifications in the physical and chemical charac-
teristics of the particulate system. These modifications 
have been shown on differential calorimetric studies, X 
Ray diffraction and infrared spectroscopy (Sarkari et al., 
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pment (Conselho Nacional de Desenvolvimento Científico 
e Tecnológico (CNPq)) and the Foundation for aid for 
Research of the State of São Paulo (Fundação de Amparo 
a Pesquisa do Estado de São Paulo (FAPESP)).
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standard deviation, n=6.
2002; Ahuja et al., 2007; Karavas et al., 2007; Kim et. 
al., 2008). Among the underlying mechanisms proposed 
to explain the increase in solubility and dissolution rate is 
the change from the crystalline state of the pharmaceutical 
compound to an amorphous state with a larger surface area 
and increased wettability and solid dissolution (Watanabe 
et al., 2003; Kim et al., 2008). The factors which led to the 
final results encountered in this study should be analyzed 
in conjunction, and may be related to the saturation of the 
carrier by the pharmaceutical, reduction in granulometry 
and interfacial tension, the conformational structure be-
tween the carrier and pharmaceutical in the SD, or modi-
fication of the crystalline state to an amorphous state. This 
last finding should be confirmed using X ray diffraction 
spectroscopy and exploratory calorimetry analysis. Stu-
dies to evaluate these hypotheses and the stability of solid 
dispersions are underway. 
CONCLUSIONS
Solubility, dissolution profile and in vitro intestinal 
absorption of PZQ are modified by SD (2:1) with hydro-
genated castor oil – PEG 60 (CR-60). The SDs obtained 
by the Fusion Method showed better results than those 
obtained by the Co-Precipitation Method. This series of 
favorable results showed that SD is a useful strategy for 
increasing the bioavailability of PZQ and could prove 
equally useful for other pharmaceutical compounds with 
poor water solubility. 
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